medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2007, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2007; 5 (4)

Morphea, a review

Rebollo DN, Gutiérrez MD, Fonte AV, Vega ME

Language: Spanish
References: 28
Page: 224-233
PDF size: 612.15 Kb.


ABSTRACT

Scleroderma, or morphea, is a chronic connective tissue disease which is characterized by sclerosis of the skin caused by excessive production of collagen. Morphea is more prevalent in women during the second and third decade. The most common type is plaque morphea. Clinically it is characterized by hyperpigmented plaques with an eythematous border during the active phase, that turn sclerotic, alopecic and anhidrótic as the disease progresses. The etiology is unknown, but genetic, infectious, traumatic and immunologic factors have been implicated. Even though it is an asymptomatic and autolimited disease, the aesthetic and functional deformities urge patients to seek treatments which at this time are unsatisfactory.


REFERENCES

  1. Pannu J, Gardner H, Shearstone JR, Smith E, Trojanowska M. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma. Arthritis Rheum. 2006; 54: 3011-3021.

  2. Sehgal V, Srivastava G, Aggarwal A. et al. Localizad scleroderma/morphea. International Journal of Dermatology. 2002; 41: 467-475.

  3. Fitzpatrick´s Dermatology in General Medicine, 6th ed. USA: Mc Graw Hill, 2003; 1709-1720.

  4. Frank H.J van den Hoogen, E. M.G.J de Jong. Clinical aspects of systemic and localized scleroderma. Current Opinion in Rheumatology 1995; 7: 546-550.

  5. Appenzeller S, Montenegro MA, Dertkigil SS et al. Neuroimaging findings in scleroderma en coup de sabre. Neurology. 2004; 62: 1585-1589.

  6. Bernardita Romero D., María Soledad Zegpi T., Celso Castillo A., Sergio González B., Sebastián Torres F. Morfea en niños: Revisión bibliográfica y puesta al día. Rev Chil Pediatr. 2004; 75(2): 166-172.

  7. Murray K, Laxer R. Scleroderma in children and adolescents. Rheumatic Diseases Clinics of North America. Vol 28. Number 3. August 2002.

  8. L. Peterson, A. Nelson, W.P Daniel, et al. The Epidemiology of Morphea (Localized Scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997; 24: 73-80.

  9. Dervis E, Dervis E. Progressive hemifacial atrophy with linear scleroderma. Pediatr Dermatol. 2005; 22: 436-439.

  10. Zulian F, Vallongo C, de Oliveira SK et al. Congenital localized scleroderma. J Pediatr. 2006; 149: 248-251.

  11. Peterson LS., Nelson AM., Su D., Subspecialty Clinics: Rheumatology and Dermatology. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70: 1068-1076.

  12. Joshi A, Al-Mutairi N, Nour-Eldin O. Congenital skin lesions presenting as morphea in a 4-year-old. Pediatr Dermatol. 2006; 23: 94-95.

  13. Aliprantis AO, Wang J, Fathman JW et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA. 2007.

  14. I. Brownell, N. Soter, A. G Franks Jr. Familial linear scleroderma (en coup de sabre) responsive to antimalarials and narrowband ultraviolet B therapy. Dermatology Online Journal 2007; 13 (1): 11

  15. Aberer E, Neumann R. Stanek G. Is localized scleroderma a Borrelia infection? Lancet 1985; ii: 278.

  16. B. Weide, B. Schittek, T. Klyscz et al. Morphea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesional skin by polymerase chain reaction. British Journal of Dermatology. 2000; 143: 780-785.

  17. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006; 18: 606-613.

  18. Rosenkranz ME, Agle LM, Efthimiou P, Lehman TJ. Systemic and localized scleroderma in children: current and future treatment options. Paediatr Drugs. 2006; 8: 85-97.

  19. Helmbold P, Fiedler E, Fischer M, Marsch WC. Hyperplasia of dermal microvascular pericytes in scleroderma. J Cutan Pathol. 2004; 31: 431-440.

  20. Aguayo et al. Severe Extrapulmonary Thoracic Restriction Caused by Morphea, a form of localized scleroderma. CHEST 104. 4. October. 1993.

  21. Gambichler T, Kreuter A, Hoffmann K, Bechara FG, Altmeyer P, Jansen T. Bilateral linear scleroderma “en coup de sabre” associated with facial atrophy and neurological complications. BMC Dermatol. 2001; 1:9.

  22. Orozco-Covarrubias L, Guzman-Meza A, Ridaura-Sanz C, Ca rras - co DD, Sosa-de-Martinez C, Ruiz-Maldonado R. Scleroderma ‘en coup de sabre’ and progressive facial hemiatrophy. Is it possible to differentiate them? J Eur Acad Dermatol Venereol. 2002; 16: 361-366.

  23. Kowalewski C, Kozlowska A, Gorska M et al. Alterations of basement membrane zone and cutaneous microvasculature in morphea and extragenital lichen sclerosus. Am J Dermatopathol. 2005; 27: 489-496.

  24. V. Falanga, T. Medsger, M. Reichlin. Antinuclear and Anti-Single- Stranded DNA Antibodies in Morphea and Generalized Morphea. Arch Dermatol 1987; 123.

  25. D. Mutasim and B. Adams. A practical guide for serologic evaluation of autoimmune connective tussue diseases. J Am Acad Dermatol 2000; 42: 159-74.

  26. Weedon, David, Strutton, Geofrey. Skin Pathology, Churchill Livingstone, New York, USA: 2002; p. 360.

  27. Weedon, David, Strutton, Geofrey. Skin Pathology, Churchill Livingstone, New York, USA: 2002; p. 46.

  28. Hulshof, Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994; 130: 1290-1293.




2020     |     www.medigraphic.com